- Adolescent Mental Health /Depression Screening
- Colorectal Cancer Screening
- Diabetes & Vascular
- General Measure Question
- HEDIS Questions
- Insurance and RELC supplemental data
- Orthopedic Measures
- Oncology Measures
- Direct Data Submission (DDS) Resources
- Preliminary HEDIS Performance Results
- Preliminary Clinical Quality Measure Results
- Technical Questions
MNCM aspirin requirements and 2018 aspirin guidelines
The aspirin guidelines released in 2018 by the American College of Cardiology relate to the use of aspirin for the primary prevention of a cardiovascular event (e.g., heart attack, stroke) if the potential benefit outweighs bleeding risk after clinician-patient risk discussion. Daily aspirin is indicated for secondary prevention when cardiovascular disease is known or an event has occurred.
The aspirin/anti-platelet component in the Optimal Diabetes Care and Optimal Vascular Care measures remains as follows:
- aspirin or anti-platelet expected for all patients with ischemic vascular disease unless a contraindication is documented.
- in the diabetes measure, those patients with the field “Patient has IVD” = 0 (No) are given a “free pass” for the component because they do not have IVD; those patients with the field “Patient has IVD” = 1 (Yes) are expected to be on daily aspirin or anti-platelets unless a contraindication is documented.
Reference: ACC's Clinician Guide to the ABCs of Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease article: https://www.acc.org/latest-in-cardiology/articles/2018/03/30/18/34/clinician-guide-to-the-abcs